Literature DB >> 28504666

Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.

Y S Jethava1, S Sica2, B Savani3, F Socola1, M Jagasia3, M Mohty4, A Nagler5, A Bacigalupo2.   

Abstract

AML is currently the first indication for allogeneic hematopoietic stem cell transplantation (allo-HSCT), as shown by international transplant registries. The conditioning regimens are classified as myeloablative conditioning, non-myeloablative or reduced intensity conditioning. Targeted radioimmunotherapy such as anti-CD45 antibody have also been added to the conditioning regimen in an attempt to improve tumor cell kill. Refinement of standard regimens has led to a reduction of non-relapse mortality, also in the older age group over 60 or 70 years of age. Relapse post allo-HSCT remains an important issue, especially for patients who undergo transplant with residual or refractory disease. In these patients, pre- and post-transplant interventions need to be considered.

Entities:  

Mesh:

Year:  2017        PMID: 28504666     DOI: 10.1038/bmt.2017.83

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  66 in total

1.  Recovery of spermatogenesis after total-body irradiation.

Authors:  Bipin N Savani; Eleftheria Kozanas; Aarthi Shenoy; A John Barrett
Journal:  Blood       Date:  2006-12-15       Impact factor: 22.113

2.  Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.

Authors:  Ute Hegenbart; Dietger Niederwieser; Brenda M Sandmaier; Michael B Maris; Judith A Shizuru; Hildegard Greinix; Catherine Cordonnier; Bernard Rio; Alois Gratwohl; Thoralf Lange; Haifa Al-Ali; Barry Storer; David Maloney; Peter McSweeney; Thomas Chauncey; Ed Agura; Benedetto Bruno; Richard T Maziarz; Finn Petersen; Rainer Storb
Journal:  J Clin Oncol       Date:  2005-12-12       Impact factor: 44.544

3.  Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation.

Authors:  E D Thomas; R A Clift; J Hersman; J E Sanders; P Stewart; C D Buckner; A Fefer; R McGuffin; J W Smith; R Storb
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-05       Impact factor: 7.038

4.  Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.

Authors:  Yu Wang; Qi-Fa Liu; Lan-Ping Xu; Kai-Yan Liu; Xiao-Hui Zhang; Xiao Ma; Zhi-Ping Fan; De-Pei Wu; Xiao-Jun Huang
Journal:  Blood       Date:  2015-05-04       Impact factor: 22.113

5.  A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation.

Authors:  Doris M Ponce; Craig Sauter; Sean Devlin; Marissa Lubin; Anne Marie Gonzales; Nancy A Kernan; Andromachi Scaradavou; Sergio Giralt; Jenna D Goldberg; Guenther Koehne; Miguel A Perales; James W Young; Hugo Castro-Malaspina; Ann Jakubowski; Esperanza B Papadopoulos; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-14       Impact factor: 5.742

6.  Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.

Authors:  Dao-Pei Lu; Lujia Dong; Tong Wu; Xiao-Jun Huang; Mei-Jie Zhang; Wei Han; Huan Chen; Dai-Hong Liu; Zhi-Yong Gao; Yu-Hong Chen; Lan-Ping Xu; Yao-Chen Zhang; Han-Yun Ren; Dan Li; Kai-Yan Liu
Journal:  Blood       Date:  2005-12-27       Impact factor: 22.113

Review 7.  The role of autologous transplantation for acute myeloid leukemia in first and second remission.

Authors:  Charles Linker
Journal:  Best Pract Res Clin Haematol       Date:  2007-03       Impact factor: 3.020

8.  Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.

Authors:  Bernard Rio; Sylvie Chevret; Stéphane Vigouroux; Patrice Chevallier; Sabine Fürst; Anne Sirvent; Jacques-Olivier Bay; Gérard Socié; Patrice Ceballos; Anne Huynh; Jérôme Cornillon; Sylvie Françoise; Faezeh Legrand; Ibrahim Yakoub-Agha; Gérard Michel; Natacha Maillard; Geneviève Margueritte; Sébastien Maury; Madalina Uzunov; Claude Eric Bulabois; Mauricette Michallet; Laurence Clement; Charles Dauriac; Karin Bilger; Eliane Gluckman; Annalisa Ruggeri; Agnès Buzyn; Stéphanie Nguyen; Tabassome Simon; Nöel Milpied; Vanderson Rocha
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-18       Impact factor: 5.742

Review 9.  How I treat the older patient with acute myeloid leukemia.

Authors:  Gert Ossenkoppele; Bob Löwenberg
Journal:  Blood       Date:  2014-12-16       Impact factor: 22.113

10.  Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.

Authors:  Je-Hwan Lee; Young-Don Joo; Hawk Kim; Hun Mo Ryoo; Min Kyoung Kim; Gyeong-Won Lee; Jung-Hee Lee; Won-Sik Lee; Jae-Hoo Park; Sung-Hwa Bae; Myung Soo Hyun; Dae-Young Kim; Sung-Doo Kim; Young Joo Min; Kyoo-Hyung Lee
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

View more
  18 in total

1.  HLA-DQB1 mismatch increase risk of severe bleeding independently in recipients of allogeneic stem cell transplant.

Authors:  Jiaqian Qi; Rui Zhang; Chengsen Cai; Hong Wang; Meng Zhou; Wenhong Shen; Yaqiong Tang; Tingting Pan; Depei Wu; Yue Han
Journal:  Ann Hematol       Date:  2021-04-12       Impact factor: 3.673

2.  Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.

Authors:  Arnon Nagler; Myriam Labopin; Bhagirathbhai Dholaria; Riitta Niittyvuopio; Johan Maertens; Xavier Poiré; Jan Cornelissen; Péter Reményi; Jean Henri Bourhis; Yves Beguin; Ram Malladi; Tessa Kerre; Wilfried Schroyens; Bipin N Savani; Mohamad Mohty
Journal:  Blood Adv       Date:  2019-07-09

3.  Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP).

Authors:  Eleni Gavriilaki; Myriam Labopin; Ioanna Sakellari; Urpu Salmenniemi; Ibrahim Yakoub-Agha; Victoria Potter; Ana Berceanu; Alessandro Rambaldi; Inken Hilgendorf; Nicolaus Kröger; Stephan Mielke; Tsila Zuckerman; Jaime Sanz; Alessandro Busca; Hakan Ozdogu; Achilles Anagnostopoulos; Bipin Savani; Sebastian Giebel; Ali Bazarbachi; Alexandros Spyridonidis; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2022-09-22       Impact factor: 5.174

4.  Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients.

Authors:  Kimberley Joanne Hatfield; Øystein Bruserud; Håkon Reikvam
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

5.  Coccidioidomycosis in Allogeneic Stem Cell Transplant Recipients: Case Series and Review of the Literature.

Authors:  Christopher F Saling; Juan Gea-Banacloche; John S Trickett; Janis E Blair
Journal:  J Fungi (Basel)       Date:  2021-04-27

6.  Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies.

Authors:  Patrice Chevallier; Pierre Peterlin; Alice Garnier; Amandine Le Bourgeois; Beatrice Mahé; Viviane Dubruille; Nicolas Blin; Cyrille Touzeau; Thomas Gastinne; Anne Lok; Yannick Le Bris; Marie C Béné; Steven Le Gouill; Philippe Moreau; Thierry Guillaume
Journal:  Oncotarget       Date:  2018-09-11

7.  Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  Francesco Saraceni; Myriam Labopin; Arne Brecht; Nicolaus Kröger; Matthias Eder; Johanna Tischer; Hélène Labussière-Wallet; Hermann Einsele; Dietrich Beelen; Donald Bunjes; Dietger Niederwieser; Tilmann Bochtler; Bipin N Savani; Mohamad Mohty; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2019-04-25       Impact factor: 17.388

8.  Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.

Authors:  Maximilian Fleischmann; Ulf Schnetzke; Jochen J Frietsch; Herbert G Sayer; Karin Schrenk; Jakob Hammersen; Anita Glaser; Inken Hilgendorf; Andreas Hochhaus; Sebastian Scholl
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-23       Impact factor: 4.322

Review 9.  Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia.

Authors:  Jodi J Lipof; Kah Poh Loh; Kristen O'Dwyer; Jane L Liesveld
Journal:  Cancers (Basel)       Date:  2018-06-04       Impact factor: 6.639

Review 10.  Thymic Engraftment by in vitro-Derived Progenitor T Cells in Young and Aged Mice.

Authors:  Jastaranpreet Singh; Mahmood Mohtashami; Graham Anderson; Juan Carlos Zúñiga-Pflücker
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.